Wells Fargo analyst Tiago Fauth raised the firm’s price target on PTC Therapeutics (PTCT) to $74 from $68 and keeps an Overweight rating on the shares. The firm notes that recovery post HD readout suggests positive sentiment into sepia launch, and Wells estimates sepia could exceed current consensus peak sales with modest assumptions — its survey suggests high intent to treat. The firm thinks base business plus sepia alone could drive upside.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics: Strategic Growth and Market Expansion Drive Buy Rating
- PTC Therapeutics upgraded to Buy from Neutral at BofA
- PTC Therapeutics price target lowered to $42 from $56 at Barclays
- PTC Therapeutics’ Earnings Call: Strong Start to 2025
- Biotech Alert: Searches spiking for these stocks today